Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Parchment

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Urology|December 22, 1999
Taxanes: an overview of the pharmacokinetics and pharmacodynamicsU Vaishampayan, R E Parchment, B R Jasti, et al.
Investigational New Drugs|January 1, 1996
Automated imaging and quantitation of tumor cells and CFU-GM colonies in microcapillary cultures: toward therapeutic index-based drug screeningM J Murphy, F Fushimi, R E Parchment, et al.
British Journal of Haematology|June 1, 1993
Megakaryocyte colony-stimulating factor (Meg-CSF) is a unique cytokine specific for the megakaryocyte lineageC L Erickson-Miller, H Ji, R E Parchment, et al.
Cancer Research|September 15, 1992
Newt squamous carcinoma proves phylogenetic conservation of tumors as caricatures of tissue renewalN P Zilakos, P A Tsonis, K Del Rio-Tsonis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 24, 1998
Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro testsR E Parchment, M Gordon, C K Grieshaber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyondK A Keyes, B Albella, P M LoRusso, et al.
Experimental Hematology|March 29, 2001
Latent hematopoietic stem cell toxicity associated with protracted drug administrationK A Keyes, J C Segovia, J A Bueren, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|August 14, 2001
High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasmaS Poondru, S Zhou, J Rake, et al.
Journal of the National Cancer Institute|February 16, 1994
In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrowR E Parchment, D A Volpe, P M LoRusso, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitroC L Erickson-Miller, R D May, J Tomaszewski, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Urology|December 22, 1999
Taxanes: an overview of the pharmacokinetics and pharmacodynamicsU Vaishampayan, R E Parchment, B R Jasti, et al.
Investigational New Drugs|January 1, 1996
Automated imaging and quantitation of tumor cells and CFU-GM colonies in microcapillary cultures: toward therapeutic index-based drug screeningM J Murphy, F Fushimi, R E Parchment, et al.
British Journal of Haematology|June 1, 1993
Megakaryocyte colony-stimulating factor (Meg-CSF) is a unique cytokine specific for the megakaryocyte lineageC L Erickson-Miller, H Ji, R E Parchment, et al.
Cancer Research|September 15, 1992
Newt squamous carcinoma proves phylogenetic conservation of tumors as caricatures of tissue renewalN P Zilakos, P A Tsonis, K Del Rio-Tsonis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 24, 1998
Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro testsR E Parchment, M Gordon, C K Grieshaber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyondK A Keyes, B Albella, P M LoRusso, et al.
Experimental Hematology|March 29, 2001
Latent hematopoietic stem cell toxicity associated with protracted drug administrationK A Keyes, J C Segovia, J A Bueren, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|August 14, 2001
High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasmaS Poondru, S Zhou, J Rake, et al.
Journal of the National Cancer Institute|February 16, 1994
In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrowR E Parchment, D A Volpe, P M LoRusso, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitroC L Erickson-Miller, R D May, J Tomaszewski, et al.
Pageof 4